| Literature DB >> 34966776 |
Kang He1, Yixiao Pan1, Hai Wang1, Jianjun Zhu1, Bijun Qiu1, Yi Luo1, Qiang Xia1.
Abstract
Background: The application of laparoscopy in donor liver acquisition for living donor liver transplantation (LDLT) has become increasingly popular in the past decade. Indole cyanide green (ICG) fluorescence technique is a new adjuvant method in surgery. The purpose was to compare the safety and efficacy of laparoscopic and open surgery in living donor left lateral hepatectomy, and to evaluate the application of ICG in laparoscopy.Entities:
Keywords: fluorescence-assisted technology; living donor liver transplantation; open donor hepatectomy; pure laparoscopic living donor hepatectomy; quality of life
Year: 2021 PMID: 34966776 PMCID: PMC8710496 DOI: 10.3389/fsurg.2021.771250
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Donors' baseline characteristics and outcomes.
|
|
|
|
|
|
|---|---|---|---|---|
| Sex (male:female) | 61:76 | 20:70 | 12:46 | 0.001*& |
| Age (years) | 30.29 ± 4.49 | 29.07 ± 4.64 | 29.88 ± 4.33 | 0.135 |
| Height (cm) | 165.42 ± 8.48 | 163.16 ± 6.44 | 164.00 ± 6.32 | 0.075 |
| Weight (kg) | 61.54 ± 11.71 | 57.12 ± 10.21 | 58.46 ± 10.42 | 0.01* |
| BMI (kg/m2) | 22.33 ± 2.81 | 21.39 ± 3.13 | 21.62 ± 2.70 | 0.04* |
| Pre-operative ALT (IU/L) | 22.84 ± 9.91 | 20.90 ± 7.65 | 23.17 ± 7.57 | 0.188 |
| Pre-operative AST (IU/L) | 19.00 ± 7.10 | 18.82 ± 6.75 | 20.12 ± 6.06 | 0.483 |
| Pre-operative TB (umol/L) | 11.68 ± 4.60 | 12.29 ± 4.48 | 12.80 ± 4.03 | 0.248 |
| Pre-operative PT (s) | 10.79 ± 0.74 | 10.68 ± 0.81 | 10.84 ± 0.78 | 0.434 |
| Pre-operative INR | 0.97 ± 0.07 | 0.96 ± 0.07 | 0.98 ± 0.07 | 0.475 |
| Operation time (min) | 146.08 ± 25.39 | 169.29 ± 26.68 | 154.34 ± 18.40 | 0.001*# |
| Intraoperatve blood loss (ml) | 108.80 ± 36.82 | 52.44 ± 18.44 | 39.48 ± 10.46 | 0.001* |
| Graft weight (g) | 270.25 ± 71.33 | 239.46 ± 41.07 | 241.38 ± 42.22 | 0.001*& |
| Post-operative hospitalization (days) | 4.64 ± 1.2 | 5.30 ± 0.98 | 4.81 ± 1.03 | 0.001*# |
| Post-operative peak ALT(IQR) (IU/L) | 181.00 (111.05–291.00) | 160.50 (101.00–336.25) | 123.50 (80–228) | 0.104 |
| Post-operative peak AST(IQR)(IU/L) | 132.00 (81.50–226.00) | 155.50 (91–282) | 119.00 (77.00–201.25) | 0.212 |
| Post-operative peak TB (umol/L) | 21.96 ± 10.08 | 21.87 ± 10.96 | 18.64 ± 7.58 | 0.082 |
| Post-operative peak PT(s) | 12.81 ± 1.09 | 12.88 ± 1.54 | 12.42 ± 0.88 | 0.061 |
| Post-operative peak INR | 1.14 ± 0.11 | 1.16 ± 0.14 | 1.12 ± 0.08 | 0.099 |
*Significant difference between ODH and PLDH; .
Recipients' baseline characteristics and outcomes.
|
|
|
|
|
|
|---|---|---|---|---|
| Age (months) | 9.95 ± 8.63 | 8.87 ± 5.08 | 8.22 ± 5.92 | 0.253 |
| Height (cm) | 68.87 ± 9.19 | 67.49 ± 5.24 | 67.79 ± 6.63 | 0.37 |
| Weight (kg) | 7.85 ± 2.30 | 7.57 ± 1.42 | 7.58 ± 1.55 | 0.47 |
| BMI (kg/cm2) | 16.39 ± 2.00 | 16.54 ± 1.81 | 16.45 ± 2.03 | 0.846 |
| Sex (male/female) | 65:72 | 51:39 | 22:36 | 0.08 |
| GRWR (%) | 2.99 ± 0.93 | 3.26 ± 0.78 | 3.19 ± 0.80 | 0.056 |
| ALB (g/L) | 30.56 ± 5.16 | 29.54 ± 5.45 | 29.70 ± 5.07 | 0.298 |
| ALT (IU/L) | 595.51 ± 732.74 | 715.29 ± 644.64 | 564.5 ± 546.28 | 0.308 |
| AST (IU/L) | 568.89 ± 487.88 | 671.89 ± 414.91 | 604.72 ± 495.72 | 0.269 |
| TB (umol/L) | 114.35 ± 92.12 | 130.96 ± 67.36 | 106.89 ± 72.79 | 0.163 |
| PT (s) | 24.44 ± 8.07 | 25.48 ± 5.34 | 24.14 ± 4.99 | 0.407 |
| INR | 2.20 ± 0.77 | 2.28 ± 0.49 | 2.18 ± 0.46 | 0.530 |
| Post-operative hospitalization (days) | 19.12 ± 8.70 | 18.80 ± 7.14 | 17.95 ± 4.28 | 0.611 |
| Post-operative ICU time (days) | 4.97 ± 1.35 | 4.84 ± 0.97 | 5.05 ± 1.09 | 0.556 |
| Post-operative death ( | 2 | 1 | 1 | 0.95 |
| Reoperation ( | 2 | 2 | 3 | 0.305 |
| Artery thrombosis ( | 1 | 0 | 0 | 0.582 |
| Portal vein complication ( | 2 | 2 | 0 | 0.531 |
| Biliary complication ( | 1 | 2 | 0 | 0.38 |
| Gastrointestinal complications ( | 1 | 1 | 1 | 0.822 |
| Infection ( | 10 | 1 | 4 | 0.102 |
| Ascites ( | 4 | 0 | 0 | 0.112 |
| Anemia ( | 2 | 0 | 0 | 0.337 |
| MODS ( | 4 | 0 | 0 | 0.112 |
*Significant difference between ODH and PLDH; .
The results of SF-36 questionnaire of donors.
|
|
|
|
|
|---|---|---|---|
| Sex (male:female) | 65:153 | 29:90 | 0.287 |
| Age (years) | 33.65 ± 6.158 | 32.6 ± 6.023 | 0.131 |
| HT | 3.14 ± 0.927 | 3.20 ± 1.094 | 0.616 |
| PF1 | 2.38 ± 0.665 | 2.43 ± 0.619 | 0.475 |
| PF2 | 2.87 ± 0.374 | 2.92 ± 0.334 | 0.265 |
| PF3 | 2.89 ± 0.375 | 2.93 ± 0.312 | 0.318 |
| PF4 | 2.80 ± 0.414 | 2.83 ± 0.397 | 0.468 |
| PF5 | 2.96 ± 0.232 | 2.98 ± 0.129 | 0.313 |
| PF6 | 2.88 ± 0.382 | 2.97 ± 0.181 | 0.004* |
| PF7 | 2.75 ± 0.520 | 2.86 ± 0.375 | 0.034* |
| PF8 | 2.86 ± 0.422 | 2.95 ± 0.220 | 0.009* |
| PF9 | 2.96 ± 0.251 | 3.00 ± 0 | 0.032* |
| PF10 | 2.96 ± 0.251 | 3.00 ± 0 | 0.032* |
| RP1 | 1.86 ± 0.345 | 1.89 ± 0.313 | 0.457 |
| RP2 | 1.87 ± 0.340 | 1.92 ± 0.279 | 0.156 |
| RP3 | 1.84 ± 0.368 | 1.89 ± 0.313 | 0.178 |
| RP4 | 1.78 ± 0.412 | 1.78 ± 0.415 | 0.951 |
| RE1 | 1.81 ± 0.392 | 1.83 ± 0.376 | 0.65 |
| RE2 | 1.83 ± 0.372 | 1.83 ± 0.376 | 0.945 |
| RE3 | 1.77 ± 0.424 | 1.84 ± 0.368 | 0.095 |
| SF1 | 4.48 ± 0.810 | 4.48 ± 0.636 | 0.982 |
| SF2 | 5.43 ± 1.110 | 5.46 ± 1.023 | 0.801 |
| BP1 | 5.62 ± 0.562 | 5.70 ± 0.427 | 0.146 |
| BP2 | 5.16 ± 1.013 | 5.28 ± 0.883 | 0.305 |
| VT1 | 4.00 ± 1.678 | 4.14 ± 1.653 | 0.468 |
| VT2 | 3.91 ± 1.455 | 3.95 ± 1.615 | 0.837 |
| VT3 | 4.65 ± 1.229 | 4.79 ± 1.127 | 0.294 |
| VT4 | 4.81 ± 1.130 | 4.87 ± 1.157 | 0.68 |
| MH1 | 4.17 ± 1.517 | 4.59 ± 1.417 | 0.015* |
| MH2 | 4.94 ± 1.254 | 5.06 ± 1.174 | 0.379 |
| MH3 | 3.83 ± 1.580 | 3.92 ± 1.675 | 0.66 |
| MH4 | 4.78 ± 1.136 | 5.02 ± 0.991 | 0.052 |
| MH5 | 4.08 ± 1.479 | 4.16 ± 1.573 | 0.655 |
| GH1 | 3.54 ± 1.074 | 3.68 ± 0.892 | 0.189 |
| GH2 | 3.82 ± 1.208 | 3.74 ± 1.131 | 0.56 |
| GH3 | 4.01 ± 1.086 | 4.11 ± 0.946 | 0.399 |
| GH4 | 3.95 ± 1.131 | 3.87 ± 1.117 | 0.533 |
| GH5 | 4.00 ± 1.032 | 4.00 ± 0.902 | 0.968 |
| PF SUM | 91.58 ± 14.057 | 94.33 ± 7.917 | 0.022* |
| RP SUM | 83.83 ± 31.559 | 86.97 ± 25.803 | 0.325 |
| BP SUM | 87.78 ± 15.171 | 89.78 ± 12.566 | 0.222 |
| GH SUM | 71.56 ± 22.072 | 72.02 ± 19.640 | 0.845 |
| VT SUM | 66.88 ± 18.969 | 68.74 ± 19.136 | 0.392 |
| SF SUM | 79.08 ± 14.999 | 79.41 ± 13.422 | 0.842 |
| RE SUM | 80.43 ± 34.231 | 83.47 ± 30.026 | 0.398 |
| MH SUM | 67.21 ± 18.119 | 70.96 ± 18.714 | 0.074 |
| HT SUM | 53.56 ± 23.182 | 55.04 ± 27.344 | 0.616 |
Values are mean (±s.d.). *Statistically significant. SUM refers to the final score calculated from the corresponding item. HT, Reported Health Transition; PF, Physical Functioning; RP, Role-Physical; RE, Role-Emotional; SF, Social Functioning; BP, Bodily Pain; VT, Vitality; MH, Mental Health; GH, General Health.